Brown Miller Wealth Management LLC Buys 3,620 Shares of Eli Lilly and Company $LLY

Brown Miller Wealth Management LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 1,083.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,954 shares of the company’s stock after buying an additional 3,620 shares during the quarter. Eli Lilly and Company comprises approximately 0.9% of Brown Miller Wealth Management LLC’s holdings, making the stock its 28th largest holding. Brown Miller Wealth Management LLC’s holdings in Eli Lilly and Company were worth $3,017,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $2,523,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Eli Lilly and Company by 499.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 18,088 shares of the company’s stock valued at $14,939,000 after buying an additional 15,071 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Eli Lilly and Company by 12.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,326 shares of the company’s stock valued at $63,038,000 after buying an additional 8,557 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks upgraded LLY from Hold to Strong Buy, a near-term catalyst that can attract buying from model-driven and income-focused investors. Zacks Research upgrade
• Positive Sentiment: Articles pushing a potential “surprise dividend” narrative have resurfaced, boosting investor interest in Lilly as a must-own 2026 idea if management signals shareholder returns. Eli Lilly’s surprise dividend story could be a 2026 must-own
• Positive Sentiment: Investor write-ups (e.g., InsiderMonkey) reiterate Lilly’s strong fundamentals and leadership in GLP-1s, supporting the case for LLY as a core holding. Positive third‑party commentary can sustain buying. What Makes Eli Lilly And Co. (LLY) a Worthy Holding?
• Positive Sentiment: MarketBeat flagged Lilly’s progress advancing two additional weight‑loss drugs (one nearing approval) — successful trial/approval news would be a major upside catalyst for revenue growth. Eli Lilly’s new drug data sets up a high‑stakes 2026
• Neutral Sentiment: Broader market strength at the start of 2026 lifted many large caps, including LLY; macro momentum (vs. company-specific news) is supporting the move. MarketBeat Week in Review – 12/29 – 01/02
• Neutral Sentiment: Coverage noting price cuts for GLP‑1 drugs in China (Novo and reports of LLY pricing moves) highlights regional pricing pressure — this could temper upside but impact is currently uncertain and depends on scale. Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
• Negative Sentiment: Two recent commercials have drawn viewer backlash and accusations over messaging; while not yet a material business issue, negative publicity can affect brand perception and invite scrutiny. Company Facing Backlash For ‘Ridiculous’ Rose Bowl Commercial
• Negative Sentiment: Another piece highlights viewer division over an alleged “pro‑obesity” message in a new ad — reputational noise that could weigh on sentiment if amplified. New Eli Lilly commercial divides viewers

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on LLY shares. Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. HSBC reissued a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Daiwa America upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Finally, BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, December 4th. Five research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $1,155.36.

Eli Lilly and Company Trading Up 0.5%

Shares of Eli Lilly and Company stock opened at $1,079.83 on Friday. The firm’s 50 day simple moving average is $1,013.16 and its two-hundred day simple moving average is $850.82. The firm has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.83, a PEG ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.